Articles

Today, 70% of clinical trials are managed in whole or in part by CROs, and experts expect the $17.8 billion clinical outsourcing industry to grow by 15% per year for at least the next five years. However, our experience, and publicly available research, indicate that the results delivered through such extensive outsourcing have been mixed. On average, sponsors benefit from a 30% reduction in cycle times as compared to trials managed internally, which can lead to as much as $150 million in additional revenue if and when a drug is brought successfully to market. However, for many, these gains in speed to market are offset by increased costs. In fact, most pharmaceutical sponsors view CROs as being comparatively expensive, and according to a study by consulting firm Campbell Alliance, 50% of outsourced trials go over budget.

Download Publication